SCHEMBL298474

SCHEMBL298474

O=C(NNC(=O)C1=CN(CC(=O)c2ccccc2)C=CC1)C1=CN(CC(=O)c2ccccc2)C=CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
CES1 P23141 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 2/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
MGAM O43451 1/20 0.37
AMY1A P0DUB6 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7805087 0.92 HDAC1 (0.40) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL287206 0.91 PTGS2 (0.47) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL660154 0.90 SMN1; SMN2 (0.39) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL660526 0.88 KAT6A (0.35) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL27854995 0.87 ALDH1A1 (0.41) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL660454 0.87 KAT6A (0.51) MEN1CYP3A4MAPTKMT2AALDH1A1
SCHEMBL660917 0.86 ALDH1A1 (0.40) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL659966 0.85 RAB9A (0.45) SMN1; SMN2KDM4EMEN1MAPK1KMT2A
SCHEMBL298933 0.84 RAB9A (0.40) SMN1; SMN2HPGDKDM4EMEN1CYP3A4
SCHEMBL658507 0.84 TSHR (0.42) SMN1; SMN2HPGDKDM4EMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT SMN1; SMN2 640/4885HPGD 202/4885KDM4E 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.